Centers For Medicare And Medicaid
CRS asks if high prices are a tool to offset CMS rebates, the FDA adds another DTC study to its lineup, and the NIH proposes making more clinical trial data public.
Patients have to be high-risk or Baby Boomers for coverage.
CMS could provide more guidance for how to crack down on healthcare fraud, the OIG asserts in a report.
Generics accounted for almost 75% of dispensed drugs in 2012, according to CMS researchers.
CMS is proposing a rule that could change how antidepressants get on Medicare Part D formularies.
The tool lets researchers tap into health data from work, meaning the year-long waits for data are over.
Official numbers are pending, but Reuters notes enrollment appears to be just 3% of the government's goal.
Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards
With a new era of transparency for doctors and life science manufacturers kicking off today, here's how some organizations are keeping physicians informed.
With a clear buffet exemption in-hand, the agency's position with respect to CME meals seems pretty clear. Industry is pushing for more clarity around the treatment of accrediting bodies.
The drug maker asked CMS to approve its Amyvid PET tracer for Medicare beneficiaries, but CMS declined, saying in a draft decision that widespread use would be of little value.
Acting administrator Marilyn Tavenner seems on track for confirmation, with the blessings of all industry stakeholders
Clinical Research Organizations, marketing research firms, accredited CME providers and lawyers look to be the big winners in CMS's Sunshine Act rule.
A BMJ study finds that medical school gift bans make doctors less likely to prescribe a new drug. Also of note: consumers think money motivates some doctors' recommendations.